{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:22:28Z","timestamp":1766514148322,"version":"build-2065373602"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12876-019-1013-1","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T12:02:30Z","timestamp":1560427350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9368-7272","authenticated-orcid":false,"given":"Akira","family":"Sakamaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenya","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Takamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Sugai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamagiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Someya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Terai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,13]]},"reference":[{"key":"1013_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/0091270003258669","volume":"44","author":"Global Burden Of Hepatitis C Working Group","year":"2004","unstructured":"Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44:20\u20139.","journal-title":"J Clin Pharmacol"},{"key":"1013_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S1089-3261(02)00078-8","volume":"7","author":"LB Seeff","year":"2003","unstructured":"Seeff LB, Hoofnagle JH. Appendix: the National Institutes of Health consensus development conference Management of Hepatitis C 2002. Clin Liver Dis. 2003;7:261\u201387.","journal-title":"Clin Liver Dis"},{"key":"1013_CR3","doi-asserted-by":"publisher","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of Hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174\u201381.","journal-title":"Ann Intern Med"},{"key":"1013_CR4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","volume":"52","author":"AC Cardoso","year":"2010","unstructured":"Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652\u20137.","journal-title":"J Hepatol"},{"key":"1013_CR5","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","volume":"315","author":"JH Hoofnagle","year":"1986","unstructured":"Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-a, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315:1575\u20138.","journal-title":"N Engl J Med"},{"key":"1013_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975\u201382.","journal-title":"N Engl J Med"},{"key":"1013_CR7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958\u201365.","journal-title":"Lancet."},{"key":"1013_CR8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/hep.510290439","volume":"29","author":"K Ikeda","year":"1999","unstructured":"Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124\u201330.","journal-title":"Hepatology."},{"key":"1013_CR9","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.cgh.2016.07.001","volume":"14","author":"R Maan","year":"2016","unstructured":"Maan R, van Tilborg M, Deterding K, et al. Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis. Clin Gastroenterol Hepatol. 2016;14:1821\u201330.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1013_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard A, Mallet V, Verkarre V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32\u20136.","journal-title":"Hepatology."},{"key":"1013_CR11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518\u201326.","journal-title":"Hepatology"},{"key":"1013_CR12","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jhep.2012.07.037","volume":"57","author":"M Schaefer","year":"2012","unstructured":"Schaefer M, Capuron L, Friebe A, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012;57:1379\u201390.","journal-title":"J Hepatol"},{"key":"1013_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2174\/1570159X14666160106155129","volume":"14","author":"EF Pinto","year":"2016","unstructured":"Pinto EF, Andrade C. Interferon-related depression: a primer on mechanisms, treatment, and prevention of a common clinical problem. Curr Neuropharmacol. 2016;14:743\u20138.","journal-title":"Curr Neuropharmacol"},{"key":"1013_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","volume":"25","author":"T Okanoue","year":"1996","unstructured":"Okanoue T, Sakamoto S, Itoh Y, et al. Side effect of high-dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25:283\u201391.","journal-title":"J Hepatol"},{"key":"1013_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.1440-1819.2000.00754.x","volume":"54","author":"S Hosoda","year":"2000","unstructured":"Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci. 2000;54:565\u201372.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1013_CR16","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/npp.2011.330","volume":"37","author":"MD McNutt","year":"2012","unstructured":"McNutt MD, Liu S, Manatunga A, et al. Neurobehavioral effects of interferon-\u03b1 in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology. 2012;37:1444\u201354.","journal-title":"Neuropsychopharmacology."},{"key":"1013_CR17","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889\u201398.","journal-title":"N Engl J Med"},{"key":"1013_CR18","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993\u20132001.","journal-title":"N Engl J Med"},{"key":"1013_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.cgh.2016.05.024","volume":"15","author":"SB Ho","year":"2017","unstructured":"Ho SB, Monto A, Peyton A, et al. Efficacy of Sofosbuvir plus ribavirin in veterans with hepatitis C virus genotype 2 infection, compensated cirrhosis, and multiple comorbidities. Clin Gastroenterol Hepatol. 2017;15:282\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1013_CR20","first-page":"496","volume":"57","author":"K Takeda","year":"2016","unstructured":"Takeda K, Noguchi R, Namisaki T, et al. Therapeutic effect of dual oral therapy with daclatasvir and asunaprevir for chronic HCV patient with depression. Kanzo (Journal of the Japan Society of Hepatology). 2016;57:496\u20138 in Japanese.","journal-title":"Kanzo (Journal of the Japan Society of Hepatology)"},{"key":"1013_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561\u201371.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"1013_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2017-000183","volume":"4","author":"S Volpato","year":"2017","unstructured":"Volpato S, Montagnese S, Zanetto A, et al. Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study. BMJ Open Gastroenterol. 2017;4(1):e000183.","journal-title":"BMJ Open Gastroenterol"},{"key":"1013_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12888-018-1735-6","volume":"18","author":"I Sundberg","year":"2018","unstructured":"Sundberg I, Lannerg\u00e5rd A, Ramklint M, et al. Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study. BMC Psychiatry. 2018;18:157.","journal-title":"BMC Psychiatry"},{"key":"1013_CR24","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608\u201317.","journal-title":"N Engl J Med"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1013-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-019-1013-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1013-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T23:19:18Z","timestamp":1591917558000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-019-1013-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,13]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1013"],"URL":"https:\/\/doi.org\/10.1186\/s12876-019-1013-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"type":"electronic","value":"1471-230X"}],"subject":[],"published":{"date-parts":[[2019,6,13]]},"assertion":[{"value":"29 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This case report did not require the review by the Institutional Review Board of Graduate School of Medical and Dental Sciences, Niigata University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A written informed consent was obtained for publication from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}